Sign in

Research summary ·

The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

ITP can raise the risk of blood clots. This review looked at clots in people with ITP at high risk. High risk meant ITP with antiphospholipid antibodies. It also meant ITP linked to autoimmune diseases that raise clot risk. All of them got a second-line treatment for ITP. These included TPO-RAs, fostamatinib, rituximab, other immune drugs, or spleen removal. The team searched for studies from 2010 to 2025.

What they found

The review took in 13 studies with 308 people in total. Of these, 40 people had a blood clot. The middle follow-up time in each study ranged from 6 to 42 months. The abstract gives clot numbers for some treatments. 30 people on TPO-RAs had a clot. 3 people on rituximab and 3 on other immune drugs had a clot. 6 people who had their spleen taken out had a clot.

What it means for patients

The authors say clots were a steady problem in this group. They say this showed up across the treatments they studied. They think the immune system in these people tends to cause clots. They say ways to lower clot risk should be planned to fit each person.

Why it is not certain yet

The abstract gives no comparison with people with ITP at lower risk. The ranges around some results were wide. Follow-up time was not the same across the studies. The abstract gives no clot numbers for fostamatinib. A review can only be as good as the studies in it.

Source

The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.

PubMed · PMID 42644834

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications